Phenazone


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Mild to moderate pain
Adult: 500 mg to 1 g every 4-8 hr. Max: 4 g/day.
Child: 12-15 yr: 500 mg once or bid. Max: 1 g daily. >15 yr: 500 mg to 1 g every 4-8 hr. Max: 4 g/day.

Oral
Acute migraine attacks
Adult: 1 g every 4-8 hr. Max: 4 g/day.
Child: >15 yr: 1 g every 4-8 hr. Max: 4 g/day.

Otic/Aural
Otic inflammation
Adult: 4-6 drops (0.5% solution) 3-4 times daily depending on the severity of inflammation.

Otic/Aural
Removal of earwax
Adult: 4-6 drops (0.5% solution) 3-4 times daily depending on the severity of inflammation.
Contraindications
Allergy to pyrazolones or other NSAIDs. G6PD deficiency, porphyria. Otic/Aural: Perforated eardrums.
Special Precautions
Pregnancy. History of blood disorders.
Adverse Reactions
Hypersensitivity reactions, nephrotoxicity. Nausea, drowsiness, convulsive crisis, agranulocytosis, leucopenia.
Potentially Fatal: Coma (large oral doses), severe skin eruptions.
Drug Interactions
May affect metabolism of drugs metabolised by liver enzymes. Metabolism may be affected by liver enzyme inhibitors or inducers.
Action
Phenazone is an NSAID.
Absorption: Absorbed from the GI tract. Peak plasma concentrations within 1-2 hr.
Distribution: Throughout the body fluids; concentrations in the saliva and breast milk reaching about the same levels as those in plasma. Protein-binding: <10%.
Metabolism: Hepatic; metabolised to 3 major metabolites.
Excretion: Mainly via urine; via bile (small amount). Elimination half-life: About 12 hr.
Storage
Otic/Aural: Store below 25°C.
CIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) / Other Ear Preparations
ATC Classification
N02BB01 - phenazone ; Belongs to the class of pyrazolone preparations. Used to relieve pain and fever.
S02DA03 - phenazone ; Belongs to the class of analgesic and anesthetic agents used as otologicals.
Disclaimer: This information is independently developed by CIMS based on phenazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in